<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445678</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-004</org_study_id>
    <secondary_id>CXA-cIAI-10-09</secondary_id>
    <secondary_id>CXA-cIAI-10-08</secondary_id>
    <nct_id>NCT01445678</nct_id>
    <nct_alias>NCT01445665</nct_alias>
  </id_info>
  <brief_title>Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of
      CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus
      meropenem (1000mg q8h)for the treatment of adults with Complicated Intraabdominal Infections
      (cIAI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately, 500 subjects will be enrolled into this study, randomized 1:1 to receive
      CXA-201 and metronidazole or comparator (meropenem). Subject participation will require a
      minimum commitment of 38 days and a maximum of 45 days. An End of Treatment (EOT) visit will
      occur within 24 hours following the last dose of study drug administration/drug
      discontinuation. A Test of Cure (TOC)/Safety visit will be conducted 26 to 30 days following
      the first dose of study drug administration. A Last Follow-up (LFU) visit will be conducted
      38 to 45 days after the first dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2011</start_date>
  <completion_date type="Actual">October 1, 2013</completion_date>
  <primary_completion_date type="Actual">October 1, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population</measure>
    <time_frame>TOC; 26-30 days after start of study drug administration</time_frame>
    <description>Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population</measure>
    <time_frame>TOC; 26-30 days after start of study drug administration</time_frame>
    <description>Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population</measure>
    <time_frame>EOT; Within 24 hours of last study drug administration</time_frame>
    <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population</measure>
    <time_frame>EOT; Within 24 hours of last study drug administration</time_frame>
    <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population</measure>
    <time_frame>LFU; 38 to 45 days after first study drug administration</time_frame>
    <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population</measure>
    <time_frame>LFU; 38 to 45 days after first study drug administration</time_frame>
    <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Complicated Intra-abdominal Infection</condition>
  <arm_group>
    <arm_group_label>CXA-201 and Metronidazole as treatment for cIAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem as treatment for cIAI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXA-201 and metronidazole</intervention_name>
    <description>CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
    <arm_group_label>CXA-201 and Metronidazole as treatment for cIAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
    <arm_group_label>Meropenem as treatment for cIAI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnoses of cIAI.

          -  Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or
             percutaneous draining of an abscess) within 24 hours of (before or after) the first
             dose of study drug.

        Exclusion Criteria:

          -  Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis;
             pancreatic abscess; or pelvic infections.

          -  Complicated intraabdominal infection managed by staged abdominal repair (STAR), open
             abdomen technique including temporary closure of the abdomen, or any situation where
             infection source control is not likely to be achieved.

          -  Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first
             dose of study drug, unless there is a documented treatment failure with such therapy.

          -  Have a concomitant infection at the time of randomization, which requires non-study
             systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only
             gram-positive activity [e.g., daptomycin, vancomycin, linezolid] are allowed).

          -  Severe impairment of renal function (estimated CrCl &lt; 30 mL/min), or requirement for
             peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (&lt; 20 mL/h urine
             output over 24 hours).

          -  The presence of hepatic disease at baseline.

          -  Considered unlikely to survive the 4 to 5 week study period.

          -  Any rapidly-progressing disease or immediately life-threatening illness (including
             respiratory failure and septic shock).

          -  Have a documented history of any moderate or severe hypersensitivity or allergic
             reaction to any β-lactam antibacterial (a history of a mild rash followed by
             uneventful re-exposure is not a contraindication to enrollment), including
             cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole,
             or nitroimidazole derivatives.

          -  Women who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellie Hershberger, Pharm.D</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudadelo-Buenos Aires</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>General Rodriguez</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Hermosa</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lujan</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merlo</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tandil</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vicente Lopez</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parana</city>
        <state>Entre Rios</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <state>Cautin</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Split</city>
        <state>Dalmatia</state>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kohtla-Jarve</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Weurttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <state>Bekes</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <state>Csongrad</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszerg</city>
        <state>Zala</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vac</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <state>Sharon</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <state>Tel Aviv</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Yahkov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <state>Gangwon-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubin</city>
        <state>Lubelskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolomin</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krafujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <results_first_submitted>January 9, 2015</results_first_submitted>
  <results_first_submitted_qc>January 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2015</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cIAI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two identical P3 protocols were initiated (NCT01445678 and NCT01445665) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. A total of 993 subjects were randomized to both arms, 493 to NCT5678 and 500 to NCT5665. Of these, 485 and 494 received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
          <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days.
Of the 979 treated subjects in the integrated analysis set, 482 received CXA.</description>
        </group>
        <group group_id="P2">
          <title>Meropenem as Treatment for cIAI</title>
          <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days Of the 979 treated subjects in the integrated analysis set, 497 received meropenem.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="497"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
          <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
        </group>
        <group group_id="B2">
          <title>Meropenem as Treatment for cIAI</title>
          <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="482"/>
            <count group_id="B2" value="497"/>
            <count group_id="B3" value="979"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="17.94"/>
                    <measurement group_id="B2" value="50.5" spread="16.85"/>
                    <measurement group_id="B3" value="50.5" spread="17.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population</title>
        <description>Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
        <time_frame>TOC; 26-30 days after start of study drug administration</time_frame>
        <population>MITT: Randomized patients, with baseline pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population</title>
          <description>Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
          <population>MITT: Randomized patients, with baseline pathogen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0"/>
                    <measurement group_id="O2" value="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the lower bound of the 2-sided 95% confidence interval was greater than -10%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population</title>
        <description>Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen</description>
        <time_frame>TOC; 26-30 days after start of study drug administration</time_frame>
        <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population</title>
          <description>Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen</description>
          <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the lower bound of the 2-sided 95% confidence interval was greater than -10%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.52</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population</title>
        <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
        <time_frame>EOT; Within 24 hours of last study drug administration</time_frame>
        <population>MITT: Microbiological Intent-to-Treat: Randomized patients, with baseline pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population</title>
          <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
          <population>MITT: Microbiological Intent-to-Treat: Randomized patients, with baseline pathogen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.23</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population</title>
        <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
        <time_frame>EOT; Within 24 hours of last study drug administration</time_frame>
        <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population</title>
          <description>Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.</description>
          <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population</title>
        <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit.</description>
        <time_frame>LFU; 38 to 45 days after first study drug administration</time_frame>
        <population>MITT: Randomized patients, with baseline pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population</title>
          <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit.</description>
          <population>MITT: Randomized patients, with baseline pathogen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5"/>
                    <measurement group_id="O2" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.09</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population</title>
        <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit</description>
        <time_frame>LFU; 38 to 45 days after first study drug administration</time_frame>
        <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
            <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
          </group>
          <group group_id="O2">
            <title>Meropenem as Treatment for cIAI</title>
            <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population</title>
          <description>Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit</description>
          <population>Microbiologically evaluable: Treated patients, complied with protocol, with pathogens susceptible to study drug.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CXA-201 and Metronidazole as Treatment for cIAI</title>
          <description>CXA-201 and metronidazole: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days</description>
        </group>
        <group group_id="E2">
          <title>Meropenem as Treatment for cIAI</title>
          <description>Meropenem: Meropenem IV infusion (1000mg q8h) for 4-14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Bilary fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Perforation bile duct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Adominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="497"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="497"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator(s) must undertake not to submit any part of the data from this protocol for publication without the prior consent of Cubist Pharmaceuticals, Inc.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two identical P3 protocols were initiated (NCT01445678 and NCT01445665) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Obi Umeh, Vice President Global Medical Sciences</name_or_title>
      <organization>Cubist Pharmaceuticals, Inc.</organization>
      <phone>781-860-8415</phone>
      <email>obiamiwe.umeh@cubist.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

